Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

350R-2

Sigma-Aldrich

FOXP1 (EP137) Rabbit Monoclonal Primary Antibody

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203

Origine biologica

rabbit

Livello qualitativo

100
500

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

EP137, monoclonal

Descrizione

For In Vitro Diagnostic Use in Select Regions

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

Confezionamento

vial of 0.1 mL concentrate (350R-24)
vial of 0.1 mL concentrate Research Use Only (350R-24-RUO)
vial of 0.5 mL concentrate (350R-25)
vial of 1.0 mL concentrate (350R-26)
vial of 1.0 mL concentrate Research Use Only (350R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (350R-27)
vial of 7.0 mL pre-dilute ready-to-use (350R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)

Produttore/marchio commerciale

Cell Marque

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

Isotipo

IgG

Controllo

lymph node, tonsil

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Visualizzazione

nuclear

Informazioni sul gene

human ... FOXP1(27086)

Descrizione generale

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique. Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies. Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform, using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

Qualità


IVD

IVD

IVD

RUO

Linkage

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Stato fisico

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Nota sulla preparazione

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Altre note

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Note legali

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
J J F Muris et al.
The Journal of pathology, 208(5), 714-723 (2006-01-10)
Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found
Lluís Colomo et al.
Blood, 101(1), 78-84 (2002-10-24)
To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single
William W L Choi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5494-5502 (2009-08-27)
Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.